Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 29, 2014 16:15 ET | Source: Repros Therapeutics Inc.

Repros Updates Androxal(R) Global Regulatory Status

Full response to November meeting submitted to FDA Repros believes all FDA questions positively addressed Company expects contract organization to officially submit NDA to FDA...
December 29, 2014 16:15 ET | Source: Repros Therapeutics Inc.

Repros Initiates Two Phase 2B Uterine Fibroid Studies

Low dose oral Proellex® study in women with fibroids and heavy menstrual bleeding initiated Vaginal administration of Proellex® in women with fibroids and heavy menstrual bleeding...
December 29, 2014 09:15 ET | Source: Repros Therapeutics Inc.

Court Rules Inventors Correctly Named on Androxal(R) Patents

THE WOODLANDS, Texas, Dec. 29, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced a federal judge in Texas has issued a definitive ruling finding correct...
November 10, 2014 09:00 ET | Source: Repros Therapeutics Inc.

Repros Therapeutics Inc.(R) Reports Third Quarter 2014 Financial Results

THE WOODLANDS, Texas, Nov. 10, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced financial results for the third quarter ended September 30, 2014. Financial...
November 06, 2014 16:15 ET | Source: Repros Therapeutics Inc.

Repros Holds Constructive Meeting With FDA Regarding Androxal(R) NDA Filing

No New Clinical Studies Requested Environmental Impact Assessment Plan Will be Discussed With FDA Prior to NDA Submission Company to Host Conference Call on Friday, November 7,...
October 27, 2014 16:01 ET | Source: Repros Therapeutics Inc.

Repros to Webcast Investor and Analyst Day on October 31st

THE WOODLANDS, Texas, Oct. 27, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced that it will host a live webcast of its Investor and Analyst Day that is being held...
October 21, 2014 16:01 ET | Source: Repros Therapeutics Inc.

Results From Long-Term Study of Androxal(R) Exhibit Positive Safety Profile

No evidence of negative effects on bone mineral density Treatment benefit is sustained with 79.3% of subjects exhibiting normal morning testosterone after 12 months of treatment (LOCF...
October 16, 2014 20:01 ET | Source: Repros Therapeutics Inc.

Upcoming FDA Meeting to be Type C Meeting

THE WOODLANDS, Texas, Oct. 16, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported that its upcoming meeting with the FDA in the first half of November will be a Type...
September 26, 2014 06:45 ET | Source: Repros Therapeutics Inc.

FDA Schedules Type B Pre-NDA Meeting With Repros

THE WOODLANDS, Texas, Sept. 26, 2014 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today reported it has been granted a Type B Pre-NDA meeting with the FDA in the first half of...
September 25, 2014 20:20 ET | Source: Repros Therapeutics Inc.

Androxal(R) Second Pivotal Study Achieves Superiority in Top Line Analysis for Both Co-Primary Endpoints Versus Marketed Topical Gel in the Treatment of Secondary Hypogonadism

44.2% of Topical T subjects below 10 million sperm/mL at end of study versus 2.4% and 0.0% respectively for Androxal® and placebo ITT (Androxal® vs. Topical T, p < 0.0001) 71.5%...